159 results on '"Roser Solans"'
Search Results
152. The neural network as a predictor of cancer in patients with inflammatory myopathies
- Author
-
Roser Solans-Laqué, Jose M. Sopena‐Sisquella, Tilman Mijares‐Boeckh‐Behrens, Miquel Vilardell-Tarrés, Enrique Romero‐Merino, Moises Labrador-Horrillo, and Albert Selva-O'Callaghan
- Subjects
Oncology ,medicine.medical_specialty ,Myositis ,Artificial neural network ,business.industry ,Immunology ,Cancer ,Prognosis ,medicine.disease ,Text mining ,Rheumatology ,Neoplasms ,Internal medicine ,medicine ,Humans ,Immunology and Allergy ,Pharmacology (medical) ,In patient ,Neural Networks, Computer ,business - Published
- 2002
153. Metástasis ósea como primera manifestación de un carcinoma suprarrenal
- Author
-
Ana Beatriz Vázquez, Roser Solans, Egmont Yagüe, and Miquel Vilardell
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,medicine ,General Medicine ,business - Published
- 2001
154. Malignant Lymphoma in Primary Sjögren Syndrome: Incidence and Risk Factors
- Author
-
Andres Lopez, Campillo Marta, Roser Solans-Laqué, Teresa Vallespi, Noelia Purroy, Mercedes Gironella, and Bosch-Gil Ja
- Subjects
medicine.medical_specialty ,Pathology ,business.industry ,Immunology ,Follicular lymphoma ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Gastroenterology ,Lymphoma ,Lymphatic system ,medicine.anatomical_structure ,Median follow-up ,hemic and lymphatic diseases ,Internal medicine ,Medicine ,Cumulative incidence ,business ,Vasculitis ,Pathological ,B cell - Abstract
Abstract 4991 Background Primary Sjögren Symdrome (PSS) is the second common systemic autoimmune rheumatic disease whose main histological feature is a focal infiltration of the exocrine glands by activated B and T lymphocytes. PSS is considered a benign autoimmune condition with a chronic indolent course. However, several reports have noted an increased incidence of malignant lymphoma with an estimated risk of up to 44 times greater than in the normal population. The aims of the present study are to assess the cumulative incidence of lymphoma in patients diagnosed of PSS, as well as to identify risk factors for developing this condition. Methods All patients diagnosed since 1988 and followed-up for longer than 2 years at our institution, were included. The pathological, immunological, and clinical features of each case of PSS were retrospectively examined. These data were cross-examined with the cumulative incidence of lymphoma in this group of patients, in order to determine common findings in patients later developing lymphoid malignancies. Results 272 patients had been diagnosed as having a PSS in this time period, of which 244 [9 males, 235 females; median age 58 years (range 17 to 88)] had been followed for more than 2 years. After a median follow up of 9.6 years, 11 (4.5%) patients developed a lymphoma, after 6 to 171 months from diagnosis. The cumulative risk for developing lymphoma at 5, 10 and 15 years was 3.4, 4.1, and 9.3%, respectively. Risk factors associated with the development of lymphoma were skin purpura/vasculitis, lymphopenia and low levels of C3 and C4 complement fractions. Low levels of C3 and C4 were also found to be associated with an earlier development of lymphoma. Conversely, skin purpura/vasculitis and lymphopenia were both associated with the development of lymphoma at a later stage. The hystological analysis showed mucosal-associated lymphoid tissue lymphoma in 5 patients, diffuse large B cell in 3, and follicular lymphoma in 3 cases. Clinically, lymphomas had extranodal presentation in 8 out of the 11 cases, involving the salivary glands in 5, lacrimal glands in 1, and soft tissues and lung in 1 case, respectively. Only 3 patients had received immunosuppressive therapy prior to the diagnosis of lymphoma, and EBV was not found in the histological examination of any of these cases. Conclusion Patients with PSS are at a higher risk for developing lymphoma. Our study suggests low levels of C3 or C4, as well as the presence of purpura or lymphopenia delimitates a group of patients at a higher risk, so that such patients may benefit from a closer follow up. Disclosures No relevant conflicts of interest to declare.
- Published
- 2009
155. Hepatitis C virus infection, Sj�gren's syndrome, and non-Hodgkin's lymphoma
- Author
-
Bosch-Gil Ja, Roser Solans-Laqué, Albert Selva-O'Callaghan, Lluis Sanchez‐Sitjes, Laia Matas‐Pericas, Dolores Rodriguez‐Pardo, and Miguel Vilardell‐Tarrés
- Subjects
Autoimmune disease ,Systemic disease ,business.industry ,Hepatitis C virus ,Immunology ,medicine.disease ,medicine.disease_cause ,Virology ,Non-Hodgkin's lymphoma ,Pathogenesis ,Rheumatology ,Immunopathology ,medicine ,Immunology and Allergy ,Pharmacology (medical) ,Viral disease ,Sjogren s ,business - Published
- 1999
156. Fetal microchimerism and inflammatory myopathies
- Author
-
Miquel Vilardell-Tarrés, Tilman Mijares Boeckh-Behrens, Albert Selva-O'Callaghan, Eva Balada-Prades, and Roser Solans-Laqué
- Subjects
Maternal-fetal exchange ,Pregnancy ,Fetus ,Dna genetics ,business.industry ,Immunology ,Medicine ,Microchimerism ,General Medicine ,business ,medicine.disease - Published
- 2001
157. Churg-Strauss syndrome: Outcome and long-term follow-up of 32 patients
- Author
-
Roser Solans Laque, Jose Angel Bosch Gil, Perez-Bocanegra, C., Albert Selva-O'Callaghan, Huguet, P., Jaume Alijotas-Reig, Orriols, R., Armadans, L., and Miguel Vilardell Tarres
158. IgG4-related disease: results from a multicenter Spanish registry
- Author
-
Manuel López-Torres, Guadalupe Fraile-Rodríguez, Gonzalo Salvador-Cervelló, Sergio Prieto-González, Miguel López-Dupla, María Jesús Barragán-González, Ángel Robles-Marhuenda, Manuel Jesús Núñez-Fernández, José Pardos-Gea, María Teresa Cruces-Moreno, Cristina López, Eva Fonseca-Aizpuru, Andreu Fernández-Codina, Fernando Martínez-Valle, Judith Gil, Arnau Casanovas-Martínez, Blanca Pinilla, Pilar Brito-Zerón, Inés DeTorres, Roser Solans-Laqué, Maria C. Cid, Universitat de Barcelona, [Fernández-Codina,A, Martínez-Valle,F, Solans-Laqué,R, Pardos-Gea,J] Internal Medicine Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain. [Pinilla,B, López,C] Hospital General Universitario Gregorio Marañón, Madrid, Spain. [DeTorres,I] Pathology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain. [Fraile-Rodríguez,G] Hospital Ramón y Caja, Madrid, Spain. [Casanovas-Martínez,A.] Consorci Sanitari Parc Taulí, Spain. [López-Dupla,M] Hospital Universitari Joan XXIII, Tarragona, Spain. [Robles-Marhuenda,A] Hospital La Paz, Madrid, Spain. [Barragán-González,MJ] Hospital Valle del Nalón, Langreo, Spain. [Cid,MC, Prieto-González,S, and Brito-Zerón,P] Hospital Clínic i Provincial, Barcelona, Spain. [Cruces-Moreno,MT] Hospital Universitario San Cecilio, Granada, Spain. [Fonseca-Aizpuru,E] Hospital de Cabueñes, Gijón, Spain. [López-Torres,M] Hospital Universitario La Princesa, Madrid, Spain. [Gil,J] Hospital Universitario Río Hortega, Valladolid, Spain. [Núñez-Fernández,MJ] Complejo Hospitalario de Pontevedra, Pontevedra, Spain. [Salvador-Cervelló,G] Hospital de Manises, Manises, Spain.
- Subjects
medicine.medical_specialty ,Epidemiology ,España ,Immunology ,Paraproteinemias ,Observational Study ,Disease ,Malignancy ,Autoimmune Diseases ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,Malalties immunològiques ,Fibrosis ,Internal medicine ,Enfermedades autoinmunes ,Diseases::Immune System Diseases::Autoimmune Diseases [Medical Subject Headings] ,parasitic diseases ,medicine ,Humans ,Registries ,Immunologia ,Espanya ,Epidemiologia ,Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings] ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Globulins::Serum Globulins::Immunoglobulins::Antibodies::Immunoglobulin Isotypes::Immunoglobulin G [Medical Subject Headings] ,business.industry ,Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Protein Disorders::Paraproteinemias [Medical Subject Headings] ,General Medicine ,medicine.disease ,Inmunosupresores ,Surgery ,Humanos ,medicine.anatomical_structure ,Multicenter study ,Spain ,Inmunoglobulina G ,Immunoglobulin G ,Immunologic diseases ,Abdomen ,IgG4-related disease ,Sistema de registros ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Registries [Medical Subject Headings] ,Presentation (obstetrics) ,business ,Pancreas ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors::Immunosuppressive Agents [Medical Subject Headings] ,Immunosuppressive Agents ,Research Article - Abstract
Journal Article; Multicenter Study; Observational Study; IgG4-related disease (IgG4-RD) is a rare entity consisting of inflammation and fibrosis that has been described in multiple organs. Concrete diagnostic criteria have been established recently and there is a lack of large series of patients.To describe the clinical presentation, histopathological characteristics, treatment and evolution of a series of IgG4-RD Spanish patients.A retrospective multicenter study was performed. Twelve hospitals across Spain included patients meeting the current 2012 consensus criteria on IgG4-RD diagnosis.Fifty-five patients were included in the study, 38 of whom (69.1%) were male. Median age at diagnosis was 53 years. Thirty (54.5%) patients were included in the Histologically Highly Suggestive IgG4-RD group and 25 (45.5%) in the probable IgG4-RD group. Twenty-six (47.3%) patients had more than 1 organ affected at presentation. The most frequently affected organs were: retroperitoneum, orbital pseudotumor, pancreas, salivary and lachrymal glands, and maxillary sinuses.Corticosteroids were the mainstay of treatment (46 patients, 83.6%). Eighteen patients (32.7%) required additional immunosuppressive agents. Twenty-four (43.6%) patients achieved a complete response and 26 (43.7%) presented a partial response (
159. EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide.
- Author
-
Seror R, Bowman SJ, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A, Gottenberg JE, Ramos-Casals M, Dörner T, Ravaud P, Vitali C, Mariette X, Asmussen K, Jacobsen S, Bartoloni E, Gerli R, Bijlsma JW, Kruize AA, Bombardieri S, Bookman A, Kallenberg C, Meiners P, Brun JG, Jonsson R, Caporali R, Carsons S, De Vita S, Del Papa N, Devauchelle V, Saraux A, Fauchais AL, Sibilia J, Hachulla E, Illei G, Isenberg D, Jones A, Manoussakis M, Mandl T, Jacobsson L, Demoulins F, Montecucco C, Ng WF, Nishiyama S, Omdal R, Parke A, Praprotnik S, Tomsic M, Price E, Scofield H, L Sivils K, Smolen J, Laqué RS, Steinfeld S, Sutcliffe N, Sumida T, Valesini G, Valim V, Vivino FB, and Vollenweider C
- Abstract
The EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) is a systemic disease activity index that was designed to measure disease activity in patients with primary SS. With the growing use of the ESSDAI, some domains appear to be more challenging to rate than others. The ESSDAI is now in use as a gold standard to measure disease activity in clinical studies, and as an outcome measure, even a primary outcome measure, in current randomised clinical trials. Therefore, ensuring an accurate and reproducible rating of each domain, by providing a more detailed definition of each domain, has emerged as an urgent need. The purpose of the present article is to provide a user guide for the ESSDAI. This guide provides definitions and precisions on the rating of each domain. It also includes some minor improvement of the score to integrate advance in knowledge of disease manifestations. This user guide may help clinicians to use the ESSDAI, and increase the reliability of rating and consequently of the ability to detect true changes over time. This better appraisal of ESSDAI items, along with the recent definition of disease activity levels and minimal clinically important change, will improve the assessment of patients with primary SS and facilitate the demonstration of effectiveness of treatment for patients with primary SS.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.